Purpose of review CXCR2 is key stimulant of immune cell migration and recruitment, especially of neutrophils. Alleviating excessive neutrophil accumulation and infiltration could prevent prolonged tissue damage in inflammatory disorders. This review focuses on recent advances in our understanding of the role of CXCR2 in regulating neutrophil migration and the use of CXCR2 antagonists for therapeutic benefit in inflammatory disorders.
INTRODUCTION
Chemokines are a large family of signaling proteins that mediate cellular migration, especially of immune cells. CXCR2 is mainly expressed on neutrophils, monocytes, natural killer cells, mast cells, and endothelial cells, and is the receptor for CXC chemokine ligands, especially CXCL8 [1] . CXCR2 mediates a G-protein-coupled receptor (GPCR) signaling cascade, with its activation starting with dissociation of the receptor from the G-protein, followed by release of the Gb subunit from the Ga subunit [2] . It has been shown that CXCR2 is phosphorylated by GPCR kinases after activation, which triggers dynamin-mediated and clathrinmediated receptor internalization mediated by barrestin1/2 and AP-2 [3] . Activated CXCR2 induces calcium release, activation of the Ras/MAPK, and PI3K signaling cascades, and it is involved in many immune responses including directed neutrophil migration [4] . Recently, Del Prete et al. [5 && ] reported that CXCR2-mediated neutrophil recruitment to sites of inflammation can be regulated by CCRL2, a seven-transmembrane domain receptor that shares structural and functional similarities with atypical chemokine receptors. CCRL2/CXCR2 heterodimerization regulates membrane CXCR2 expression and function, providing a novel mechanism for its regulation. For example, CXCR2-mediated signaling was impaired in CCRL2-deficient neutrophils.
Neutrophils express over 30 receptor types including pattern recognition receptors, cytokine receptors, adhesion receptors, and GPCRs [6] . They play a central role in innate immunity via sensing various stimuli through these receptors, acting as the first line of host defense against infection. Neutrophils migrate to sites of infection to then control bacterial burden. A recent study suggests that neutrophil recruitment during inflammation proceeds in two phases: an early phase, mediated by shortlived signals, followed by an amplification phase to prolong neutrophil recruitment and activation, which is mediated by signaling cascades through leukotriene-B4 and CXCL8-family chemokines [7, 8] . Excess neutrophil infiltration can enhance the inflammatory response and prolong tissue damage [9] [10] [11] . Balancing pathogen control and inflammation-related tissue injury is largely dependent upon neutrophil homeostasis as well as the degree of neutrophil activation in the presence of various stimuli. Regulating neutrophil CXCR2 and its ligand expression are potential therapeutic targets for controlling neutrophil recruitment and function in inflammatory disorders.
THE EFFECT OF CXCR2 SIGNALING ON HEMATOPOIETIC CELL MOBILIZATION AND RECRUITMENT
CXCR2 is known to be involved in neutrophil recruitment from peripheral blood to inflamed tissue. Chou et al. illustrated the amplification stage of neutrophil recruitment in an inflammatory arthritis modal and showed that cytokines such as IL-1b and chemokines such as CXCL12 released by activated neutrophils activate synovial cells. These activated synovial tissues then produced ligands for CXCR1 and CXCR2 to further promote sequential neutrophil activation [12] . CXCR2 is also responsible for neutrophil migration to tumors in mouse cancer models. Significantly, CXCR2 expression was significantly lower in tumor-associated neutrophils than those in the bone marrow and peripheral blood [13] , with endogenous IFN-b inhibiting CXCR2-induced neutrophil recruitment by reducing CXCR2 ligand expression and chemokine gradients. Bian et al. recently reported myeloid-derived suppressor cells (MDSCs) with high CXCR2 expression that promoted tumor progression. These G-MDSCs were functionally different to mature neutrophils and accumulated in tumors to immunosuppress T cells [14 & ].
The role of CXCR2 in neutrophil migration from bone marrow to peripheral blood has also been well explored. ELR þ chemokines such as CXCL8 stimulated neutrophil mobilization in a CXCR1-dependent and CXCR2-dependent manner [15] . In addition, neutrophils lacking CXCR2 have impaired emigratory capacity [16] . Eash et al. [17] showed that CXCR2 signaling antagonized CXCR4 to regulate neutrophil release from the bone marrow. More recently, granulocyte-colony-stimulating factor (G-CSF) and CXCR2 have been shown to interact during inflammation. G-CSF is a well known neutrophil-mobilizing cytokine [18] , and its mobilization function is believed to be mediated by CXCR2 ligands [19] , as G-CSF failed to mobilize neutrophils in CXCR2-deficient mice. In an arthritis modal, anti-G-CSF receptor blockade not only significantly reduced cell adhesion in joints, but also reduced CXCR2-expressing circulating neutrophils [20 & ]. On the other hand, the activation of CRCR2 can also be modulated by G-CSF. Compared with G-CSF, CXCR2-induced neutrophil mobilization much more quickly [21, 22] , indicating a distinct mobilization mechanism. Bajrami et al. [23 && ] revealed that Escherichia coli-induced G-CSF increases during the early stages of inflammation inhibited rapid CXCR2-mediated neutrophil mobilization. G-CSF was elevated after CXCR2 ligands macrophage inflammatory protein 2 and keratinocyte chemoattractant were expressed, and this elevation inhibited CXCR2-mediated neutrophil chemotaxis. Further, only CXCR2-induced neutrophil mobilization from the bone marrow was suppressed by G-CSF and not other chemoattractants such as leukotriene-B4, C5a, or fMLP. The regulatory function of G-CSF on CXCR2 signaling indicated that exaggerated neutrophil mobilization may be achieved by targeting G-CSF-elicited pathways.
CXCR2 signaling has also been implicated in the mobilization of hematopoietic stem/progenitor cells (HSPCs). Clinically, HSPCs are usually mobilized from the bone marrow to peripheral blood
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using a G-CSF regimen. ] reported an alternative HSPC mobilization regimen, a combination of GROb and AMD3100 (a CXCR2 agonist and a CXCR4 antagonist, respectively), which increased HSPC mobilization by elevating matrix metalloproteinase 9. Importantly, the new regimen displayed better engraftment and greater donor chimerism compared with the G-CSF regimen. ] investigated the molecular mechanism of NETs during thrombosis development in a heparininduced thrombocytopenia model. They showed that neutrophils migrated via a CXCR2-dependent mechanism to accumulate in thrombi, and CXCR2 antagonist therapy reduced neutrophil counts in thrombi with clinical significance.
THE ROLE OF CXCR2 IN INFECTION AND INFLAMMATION
The role of CXCR2 signaling in other inflammatory diseases has also been investigated in recent years. CXCR2 has been considered as a potential pharmacological target in controlling inflammatory damage in the pathogenesis of chronic obstructive pulmonary disease (COPD) [ ]. These results suggest that the interaction between neutrophils and the microbiome may be a promising target in colitis treatment and emphasize the role of CXCR2 in regulating intestinal neutrophil recruitment. 
CONCLUSION
It is now well established that CXCR2 is a crucial regulator of hematopoietic cell homeostasis, migration, and recruitment, and is implicated in a variety of inflammatory diseases and cancer. Therefore, CXCR2 and its related signaling pathways could be promising pharmacological targets in these diseases. Efforts still need to be made to fully understand the pathophysiological role of CXCR2 signaling in health and disease and to define optimal regimens with improved compounds with ideal 
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